C4 Therapeutics, a clinical-stage biopharmaceutical company, has reported significant developments in its collaboration agreements and clinical trials. The company has amended its agreement with Roche, adjusting the timing of Roche's option rights to license and commercialize products directed at two collaboration targets. Roche will pay C4 Therapeutics fees upon progression to certain development phases and has potential to pay up to $273 million in milestone payments, plus royalties on net sales. C4 Therapeutics has also completed its research term with Biogen, focusing on novel treatments for neurological conditions. The company received milestone payments from Biogen totaling $16 million in 2024. Additionally, C4 Therapeutics' collaboration with Calico on aging diseases, including cancer, has concluded its research term. Financially, C4 Therapeutics recognized $15.36 million in revenue from collaboration agreements...Show More

C4 Therapeutics, a clinical-stage biopharmaceutical company, has reported significant developments in its collaboration agreements and clinical trials. The company has amended its agreement with Roche, adjusting the timing of Roche's option rights to license and commercialize products directed at two collaboration targets. Roche will pay C4 Therapeutics fees upon progression to certain development phases and has potential to pay up to $273 million in milestone payments, plus royalties on net sales. C4 Therapeutics has also completed its research term with Biogen, focusing on novel treatments for neurological conditions. The company received milestone payments from Biogen totaling $16 million in 2024. Additionally, C4 Therapeutics' collaboration with Calico on aging diseases, including cancer, has concluded its research term. Financially, C4 Therapeutics recognized $15.36 million in revenue from collaboration agreements in Q3 2024, contributing to a total of $30.41 million over nine months. The company's net loss for Q3 2024 was $24.66 million, with a basic and diluted net loss per share of $0.35. C4 Therapeutics continues to advance its clinical trials, including its product candidates cemsidomide for multiple myeloma and non-Hodgkin lymphomas, and CFT1946 for BRAF V600X mutant solid tumors.